Michael Burkes Brophy Sells 3,235 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRAGet Free Report) CFO Michael Burkes Brophy sold 3,235 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $65.09, for a total value of $210,566.15. Following the completion of the transaction, the chief financial officer now owns 92,927 shares in the company, valued at approximately $6,048,618.43. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Michael Burkes Brophy also recently made the following trade(s):

  • On Tuesday, January 23rd, Michael Burkes Brophy sold 2,202 shares of Natera stock. The shares were sold at an average price of $65.86, for a total value of $145,023.72.
  • On Friday, December 29th, Michael Burkes Brophy sold 1,377 shares of Natera stock. The shares were sold at an average price of $62.29, for a total value of $85,773.33.

Natera Price Performance

NTRA stock opened at $65.94 on Thursday. The business has a fifty day moving average of $61.14 and a two-hundred day moving average of $52.98. The company has a quick ratio of 4.23, a current ratio of 4.37 and a debt-to-equity ratio of 0.36. The stock has a market cap of $7.93 billion, a price-to-earnings ratio of -14.59 and a beta of 1.28. Natera, Inc. has a 52-week low of $36.90 and a 52-week high of $68.92.

Natera (NASDAQ:NTRAGet Free Report) last posted its earnings results on Wednesday, November 8th. The medical research company reported ($0.95) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.96) by $0.01. The company had revenue of $268.30 million during the quarter, compared to analysts’ expectations of $259.27 million. Natera had a negative return on equity of 72.98% and a negative net margin of 50.50%. The firm’s quarterly revenue was up 27.4% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.25) earnings per share. As a group, research analysts anticipate that Natera, Inc. will post -3.88 earnings per share for the current year.

Institutional Investors Weigh In On Natera

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NTRA. abrdn plc acquired a new stake in shares of Natera in the fourth quarter valued at $3,214,000. Oliver Lagore Vanvalin Investment Group grew its stake in shares of Natera by 109.3% in the fourth quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock valued at $47,000 after buying an additional 389 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Natera by 15.7% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 23,844 shares of the medical research company’s stock valued at $1,494,000 after buying an additional 3,228 shares in the last quarter. WCM Investment Management LLC grew its stake in shares of Natera by 101.2% in the fourth quarter. WCM Investment Management LLC now owns 145,996 shares of the medical research company’s stock valued at $9,058,000 after buying an additional 73,419 shares in the last quarter. Finally, Cerity Partners LLC grew its stake in shares of Natera by 1,043.3% in the fourth quarter. Cerity Partners LLC now owns 90,423 shares of the medical research company’s stock valued at $5,664,000 after buying an additional 82,514 shares in the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on NTRA. The Goldman Sachs Group raised their target price on Natera from $64.00 to $80.00 and gave the company a “buy” rating in a research report on Monday. UBS Group reduced their price objective on Natera from $76.00 to $70.00 and set a “buy” rating on the stock in a research report on Thursday, November 9th. TD Cowen lifted their price objective on Natera from $82.00 to $87.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 12th. BTIG Research lifted their price objective on Natera from $75.00 to $85.00 and gave the stock a “buy” rating in a research report on Friday, December 29th. Finally, StockNews.com began coverage on Natera in a research report on Thursday, October 5th. They set a “sell” rating on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $71.54.

View Our Latest Research Report on Natera

Natera Company Profile

(Get Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Featured Stories

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.